Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial

Circulation

Volumn 105, Issue 7, 2002, Pages 788-793

  Simons, Michael ^a   Annex, Brian H ^b   Laham, Roger J ^c   Kleiman, Neal ^d   Henry, Timothy ^e   Dauerman, Harold ^f   Udelson, James E ^g   Gervino, Ernesto V ^c   Pike, Marilyn ^h   Whitehouse, M J ^h   Moon, Thomas ^h   Chronos, Nicolas A ⁱ  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e HENNEPIN COUNTY MEDICAL CENTER   (United States)

^f University of Massachusetts   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ Atlanta Cardiology Group   (United States)

Author keywords

Angina; Angiogenesis; Coronary disease; Revascularization; Trials

Indexed keywords

RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EXERCISE TOLERANCE; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; INTRACORONARY INFUSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REVASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EXERCISE TEST; EXERCISE TOLERANCE; EYE DISEASES; FEMALE; FIBROBLAST GROWTH FACTOR 2; HEALTH STATUS; HUMANS; HYPOTENSION; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; QUESTIONNAIRES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0037133306     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0802.104407     Document Type: Article

References (30)

1. Mechanisms of angiogenesis and arteriogenesis
2. Therapeutic angiogenesis in cardiology using protein formulations
3. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris
4. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase 1 open-label dose escalation study
5. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease
6. Development and evaluation of the Seattle Angina Questionnaire: A new functional status measure for coronary artery disease
7. Fibroblast growth factors as multifunctional signaling factors
8. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: A goal for therapeutic angiogenesis?
9. Signal transduction by fibroblast growth factor receptors
10. Syndecan-4-mediated signaling
11. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model
12. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury
13. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: A comparison of angiographic, echocardiographic and coronary flow parameters
14. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
15. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia
16. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution
17. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
18. Delivery strategies to achieve therapeutic myocardial angiogenesis
19. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
20. Clinical trials in coronary angiogenesis: Issues, problems, consensus: An expert panel summary
21. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: Evidence for a dose-dependent effect
22. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
23. Direct myocardial injection of phVEGF165: Results of complete patient cohort in phase 1/2 clinical trial
24. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease: Veterans Affairs ACME investigators
25. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
26. Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: A comparison with positron emission tomography and coronary angiography
27. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction
28. Coronary angiogenesis: Detection in vivo with MR imaging sensitive to collateral neocirculation: Preliminary study in pigs
29. Results of intracoronary recombinant human vascular endothelial growth factor (rhVEGF) administration trial
30. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease